BETA TRUTIDE -The Next-Gen Triagonist for Obesity, Diabetes & Liver Health

BETA TRUTIDE RETATRUTIDE (Triple Agonist Injection) The Next-Gen Triagonist for Obesity, Diabetes & Liver Health Contents: Retatrutide 5mg Vials (for SC/IM Administration) × 5 Sterile Water for Injection (2ml Ampoules) × 5 What is BETA TRUTIDE? BETA TRUTIDE is an investigational, first-in-class triple hormone receptor agonist designed to tackle obesity, type 2 diabetes, and nonalcoholic steatohepatitis (NASH). Unlike existing GLP-1 or dual agonists, BETA TRUTIDE uniquely targets three complementary metabolic pathways for unmatched efficacy: GLP-1 Receptor: Stimulates insulin secretion, reduces appetite, and delays gastric emptying. GIP Receptor: Enhances insulin release and optimizes fat metabolism. Glucagon Receptor: Elevates energy expenditure and promotes fat breakdown through thermogenesis. This triagonist approach amplifies metabolic control, delivering superior weight loss, enhanced glycemic regulation, and marked reductions in liver fat. How BETA TRUTIDE Helps 1. Weight Management Demonstrates robust weight loss (greater than dual agonists in early studies). Encourages visceral fat reduction and sustained BMI improvements. Boosts energy expenditure through glucagon-driven thermogenesis. 2. Diabetes Care Improves fasting and postprandial glucose control. Achieves significant HbA1c reduction, even in resistant cases. Offers lower hypoglycemia risk due to glucose-dependent action. 3. Liver Health (NASH Benefits) Reduces hepatic fat accumulation. Improves liver function markers. Potential therapeutic option for NASH patients with metabolic syndrome. Administration & Storage Route of Administration: Subcutaneous (SC) or Intramuscular (IM) injection. Storage Guidelines: Before Reconstitution: Store at room temperature (≤25°C), protected from heat and sunlight. After Reconstitution: Refrigerate at 2–8°C; use within the recommended time. Do not freeze or expose to direct light. Dosage Protocol Recommended Titration Schedule: Initial Dose: 2mg once weekly for 4 weeks. Escalation: Increase to 4mg, 8mg, or up to 12mg weekly as tolerated. Dose Increments: Every 4 weeks under medical supervision. This gradual titration helps minimize GI side effects (nausea, vomiting) and ensures better compliance. All dose adjustments should be supervised by a healthcare professional. For quality assurance, you can review the Certificate of Analysis (COA) Comparison: VITAGLUCIDE (Tirzepatide) vs. BETA TRUTIDE (Retatrutide) VITAGLUCIDE (Tirzepatide) is a powerful dual-acting incretin therapy that combines GIP and GLP-1 receptor agonism. It has proven to be highly effective in managing type 2 diabetes and obesity, delivering significant weight loss, better glycemic control, and cardiovascular benefits. Its dual mechanism has made it a preferred option for patients seeking well-documented outcomes with a balance of efficacy and tolerability. BETA TRUTIDE (Retatrutide), however, represents the next leap forward in incretin-based therapy. By targeting three receptors—GLP-1, GIP, and Glucagon—it provides broader and more powerful metabolic effects. In addition to superior weight loss and glucose regulation compared to dual agonists, BETA TRUTIDE also shows promising benefits in reducing liver fat, making it a potential breakthrough therapy for nonalcoholic steatohepatitis (NASH). This triple-action profile positions it as a more comprehensive solution for metabolic disease management. In short, VITAGLUCIDE delivers excellent dual-action results for diabetes and obesity, while BETA TRUTIDE raises the bar with its triagonist approach, offering broader metabolic benefits that extend into liver health. The choice depends on whether a patient requires proven dual-agonist therapy or is ready for a next-generation treatment with wider potential advantages. Contraindications Avoid BETA TRUTIDE if: Personal/family history of medullary thyroid carcinoma (MTC). Diagnosis of Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Known hypersensitivity to retatrutide or formulation excipients. Special Precautions Thyroid Tumors C-cell tumors observed in animal studies; human relevance is uncertain. Avoid use in high-risk individuals and monitor as advised by clinician. Pancreatitis Discontinue if severe or persistent abdominal pain occurs. Renal Impairment Use caution—GI side effects causing dehydration may worsen kidney function. Diabetic Retinopathy Rapid glycemic improvements can transiently worsen retinopathy—monitor closely. Pregnancy & Lactation Not recommended; safety not established. Adverse Drug Reactions Common: Nausea, diarrhea, vomiting, constipation, appetite suppression, abdominal discomfort. Rare: Injection site reactions, hypersensitivity, dehydration, gallbladder dysfunction, thyroid changes, visual disturbances. Drug Interactions Insulin or Sulfonylureas: Increased risk of hypoglycemia — dose adjustments and monitoring required. Oral Medications: Delayed gastric emptying may affect absorption — review concomitant medications. Why Choose BETA TRUTIDE? ✅ Triple hormone receptor agonist (GLP-1 + GIP + Glucagon). ✅ Superior weight loss, glucose control, and liver fat reduction. ✅ Potential breakthrough therapy for diabetes + obesity + NASH. ✅ Flexible titration for tailored metabolic impact. Disclaimer Product images are representational; actual packaging may vary. For investigational/medical use under healthcare supervision only — not for self-administration without a clinician's guidance. Store as directed to preserve efficacy.